EUVIMEDEUVIMED entdecken
Open Access

Bridging the Gap: Inclusion of Pregnant Women in Clinical Drug Trials

Eileen F O'Connor McFerran, Sara K Quinney iD

Clinical Chemistry · 30.12.2025 · 72 (1) · 7-10

DOI: 10.1093/clinchem/hvaf149 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Chemistry, online erschienen am 30.12.2025. Verfasst von Eileen F O'Connor McFerran und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, IN, United States. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 7 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS, National Institute of Child Health and Human Development (NICHD) Maternal and Pediatric Precision In Therapeutics (MPRINT).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

More than 3.5 million births occur annually in the United States (1). Many of these pregnancies are affected by acute or chronic medical conditions such as infection, hypertension, diabetes, and obesity, which require therapeutic intervention. Over 90% of pregnant women take at least one medication during pregnancy, and 30% take 5 or more (2). Despite this, women have long been underrepresented in clinical trials and pregnant or lactating women largely excluded, leaving a knowledge gap in appropriate and safe use of medications in pregnancy. This gap is due, in part, to the historical classification of pregnant women as a vulnerable population, requiring additional protections from clinical trials. While pregnancy or lactation may require additional considerations for research, it does not limit decision-making capacity or the ability to obtain informed consent. Pregnant and lactating patients are complex and understudied, resulting in limited data to guide clinical care. The exclusion of pregnant and lactating individuals from clinical drug trials is a side-effect of attempts to protect potential harm to offspring. Partially in response to the thalidomide tragedy, the FDA excluded women of childbearing potential from early drug research in 1977. The NIH Revitalization Act of 1993 mandated inclusion of women in clinical research and the FDA updated their guidelines allowing participation of women of reproductive age in drug studies. However, it was not until 2019 that pregnant women were no longer labeled as a vulnerable population (3). As demonstrated by Bilinski et al. in an April 2025 study, pregnant women continue to be excluded from clinical drug trials (4). The study evaluated randomized controlled drug trials registered in ClinicalTrials.gov between 2008 and 2023 to determine whether pregnant patients were included, excluded, or not mentioned explicitly. Out of 44 160 trials that were included, only 362 (0.8%) included pregnant patients. Pregnant patients were excluded in 75% and not explicitly mentioned in 24% of trials. Notably, 94% of trials that included pregnant patients excluded any nonpregnant participants, indicating that their focus was specific to pregnancy. Trials including pregnant patients were more often open label, focused on prevention, and less likely to be industry sponsored. These trials were predominantly related to labor and delivery, pregnancy-related conditions and preterm labor (4).

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, IN, United States.
  • Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, United States.

ORCID-Profile: Sara K Quinney

Förderung

  • NICHD NIH HHS
  • National Institute of Child Health and Human Development (NICHD) Maternal and Pediatric Precision In Therapeutics (MPRINT)

Zitieren

APA

O'Connor McFerran, E. F., & Quinney, S. K. (2025). Bridging the Gap: Inclusion of Pregnant Women in Clinical Drug Trials. Clinical Chemistry, 72(1), 7-10. https://doi.org/10.1093/clinchem/hvaf149

Vancouver

O'Connor McFerran EF, Quinney SK. Bridging the Gap: Inclusion of Pregnant Women in Clinical Drug Trials. Clinical Chemistry. 2025;72(1):7-10. doi:10.1093/clinchem/hvaf149

BibTeX
@article{OConnorMcFerran2025,
  author = {O'Connor McFerran, Eileen F and Quinney, Sara K},
  title = {Bridging the Gap: Inclusion of Pregnant Women in Clinical Drug Trials},
  journal = {Clinical Chemistry},
  year = {2025},
  volume = {72},
  number = {1},
  pages = {7--10},
  doi = {10.1093/clinchem/hvaf149}
}
Kostenlos starten →